Alisertib
A potent and highly selective inhibitor of Aurora A with IC50 of 1.2 nM; has less activity against Aurora B (IC50=396.5 nM) and a 205-kinase panel; inhibits proliferation of human tumor cell lines in vitro and produces tumor growth inhibition in solid tumor xenograft models. (In Vitro) :Levetiracetam increases the transcription of HDACs and recruits corepressor complex on O6-Methylguanine-DNA-methyltransferase (MGMT) promoter, thus silencing its activity.Levetiracetam sensitizes (40 μg/mL) glioblastoma multiforme stem-like cells (GSCs) to Temozolomide (250 μM) treatment.MGMT expression is downregulated in GCSCs treated with Levetiracetam (40 μg/mL) . (In Vivo) :Levetiracetam (10, 25, or 50 mg/kg) suppresses behavioral and electrographic seizure activity during neonatal hypoxia.
Product Specifications
CAS Number
1028486-01-2
Product Name Alternative
MLN 8237 | MLN8237 | MLN-8237
Purity
>98% (HPLC)
Solubility
DMSO: 9.33 mg/mL
Smiles
O=C (O) C1=CC=C (NC2=NC=C3C (C4=CC=C (Cl) C=C4C (C5=C (OC) C=CC=C5F) =NC3) =N2) C=C1OC
Molecular Formula
C27H20ClFN4O4
Molecular Weight
518.9235
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Benzoic acid, 4-[[9-chloro-7- (2-fluoro-6-methoxyphenyl) -5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxy-
Available Sizes
Explore Other Products
Browse additional items from our catalog